VEC has been the topic of several other research reports. Royal Bank of Canada raised Vectura Group to a sector performer rating and set a GBX 119 ($1.64) price target on the stock in a report on Thursday, December 14th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Vectura Group in a report on Monday, January 15th. Numis Securities reiterated a buy rating and set a GBX 170 ($2.35) price objective on shares of Vectura Group in a research report on Thursday, January 4th. Shore Capital reiterated a hold rating on shares of Vectura Group in a research report on Wednesday. Finally, Citigroup reiterated a buy rating and set a GBX 155 ($2.14) price objective on shares of Vectura Group in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of GBX 139.38 ($1.93).
Shares of VEC stock opened at GBX 80.65 ($1.11) on Wednesday. Vectura Group has a 1-year low of GBX 70 ($0.97) and a 1-year high of GBX 166.97 ($2.31).
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.